Cargos activos de Karen Callewaert
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Oxford Biomedical Research, Inc.
Oxford Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Oxford Biomedical Research (OBR) develops, manufactures and markets assay kits, recombinant proteins and antibodies for biomedical research and drug discovery. The company's primary focus is on the identification and assay of biomarkers for oxidative stress and chronic inflammation, two major risk factors for multiple diseases. OBR is employing proprietary technology to develop tissue and disease specific biomarkers. ProteoMine™ is a cost effective tool for removing high abundance proteins for biomarker discovery. ToxProfiler™ technology captures and detects oxidized proteins in blood correlated with organ-specific toxicity and disease. New platform technologies such as Toxic proteomics and Metabolomics are being applied, adapted and modified into new and practical ways for the diagnosis of early onset disease and for the prevention of diseases. The company was founded in 1984 and is headquartered in Rochester Hills, MI. | Treasurer | 17/05/2011 | - |
Historial de carrera de Karen Callewaert
Estadísticas
Internacional
Estados Unidos | 2 |
Operativa
Treasurer | 1 |
Sectorial
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Oxford Biomedical Research, Inc.
Oxford Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Oxford Biomedical Research (OBR) develops, manufactures and markets assay kits, recombinant proteins and antibodies for biomedical research and drug discovery. The company's primary focus is on the identification and assay of biomarkers for oxidative stress and chronic inflammation, two major risk factors for multiple diseases. OBR is employing proprietary technology to develop tissue and disease specific biomarkers. ProteoMine™ is a cost effective tool for removing high abundance proteins for biomarker discovery. ToxProfiler™ technology captures and detects oxidized proteins in blood correlated with organ-specific toxicity and disease. New platform technologies such as Toxic proteomics and Metabolomics are being applied, adapted and modified into new and practical ways for the diagnosis of early onset disease and for the prevention of diseases. The company was founded in 1984 and is headquartered in Rochester Hills, MI. | Commercial Services |
- Bolsa de valores
- Insiders
- Karen Callewaert
- Experiencia